Godavari Drugs

Who are the top shareholders of the Godavari Drugs?

The top shareholders of Godavari Drugs include promoter Sushma Kakani with 15.34%, Highcrestt Global Company Ltd as the largest public shareholder at 2.66%, and individual investors holding a combined 39.93%. There are currently no mutual funds or foreign institutional investors in the company.

The top shareholders of Godavari Drugs include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sushma Kakani, with a stake of 15.34%. Additionally, Highcrestt Global Company Ltd is the highest public shareholder, owning 2.66% of the company. Individual investors collectively hold 39.93% of the shares. Notably, there are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

how big is Godavari Drugs?

As of Jun 06, Godavari Drugs Ltd has a market capitalization of 72.67 Cr, classifying it as a Micro Cap company, with recent net sales of 113.35 Cr and a net profit of 4.38 Cr over the last four quarters.

Market Cap: As of Jun 06, Godavari Drugs Ltd has a market capitalization of 72.67 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, Godavari Drugs reported a sum of Net Sales of 113.35 Cr and a sum of Net Profit of 4.38 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is also Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 38.97 Cr, and the Total Assets amount to 134.75 Cr.

Who are in the management team of Godavari Drugs?

As of March 2023, the management team of Godavari Drugs includes Mukund Kakani (Managing Director), Mohit Jaju (Whole Time Director & CFO), and several non-executive directors, including Ghanshyam Jaju (Chairman) and S A Hussain. Venkatesh Achanta serves as the Company Secretary & Compliance Officer.

As of March 2023, the management team of Godavari Drugs includes the following individuals:<BR><BR>1. Mukund Kakani - Managing Director<BR>2. S A Hussain - Non-Executive & Independent Director<BR>3. Mohit Jaju - Whole Time Director & CFO<BR>4. Ramesh Babu Telugu - Non-Executive & Independent Director<BR>5. Vimala B Madon - Non-Executive & Independent Director<BR>6. Ghanshyam Jaju - Chairman (Non-Executive)<BR>7. Mahindra Uday Bhalerao - Non-Executive Director<BR>8. Venkatesh Achanta - Company Secretary & Compliance Officer<BR><BR>As of March 2023, the management team of Godavari Drugs comprises a diverse group of directors and executives, each holding specific roles within the company.

When is the next results date for Godavari Drugs?

No Upcoming Board Meetings

Has Godavari Drugs declared dividend?

No Dividend History Available

Who are the peers of the Godavari Drugs?

Godavari Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Lasa Supergeneri, Sunil Healthcare, and Vivo Bio Tech. In terms of management risk, growth, and capital structure, Sun Pharma and Cipla perform excellently, while Godavari Drugs shows average management risk and below-average growth.

Peers: The peers of Godavari Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Lasa Supergeneri, Sunil Healthcare, and Vivo Bio Tech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Rajnish Wellness, Godavari Drugs, Vivo Bio Tech, and Vasundhara Rasy. Below Average management risk is noted for Lasa Supergeneri and Sunil Healthcare. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Rajnish Wellness, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Godavari Drugs, Vivo Bio Tech, Lasa Supergeneri, and Sunil Healthcare. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good for Torrent Pharma, Average for Lasa Supergeneri, and Below Average for Rajnish Wellness, Godavari Drugs, Sunil Healthcare, and Vivo Bio Tech.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Rajnish Wellness has the lowest at -83.99%. Godavari Drugs has a 1-year return of 3.44%, which is significantly higher than Rajnish Wellness but lower than Divi's Lab. Additionally, the peers with negative six-month returns include Rajnish Wellness, Lasa Supergeneri, Sunil Healthcare, and Vasundhara Rasy.

What is the technical trend for Godavari Drugs?

As of May 30, 2025, Godavari Drugs shows a mildly bearish trend, influenced by daily moving averages and monthly indicators, despite mixed signals from weekly MACD and KST.

As of 30 May 2025, the technical trend for Godavari Drugs has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, creating a mixed signal. The monthly MACD and Bollinger Bands are bearish, which adds to the overall bearish sentiment. The RSI shows no signal in both weekly and monthly time frames, indicating a lack of momentum. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly indicators.

What does Godavari Drugs do?

Godavari Drugs Limited manufactures Active Pharmaceutical Ingredients (API) and drug intermediates in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 255 Cr and a net profit of 9 Cr, with a market cap of INR 66 Cr.

Overview: <BR>Godavari Drugs Limited is engaged in the manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in an unspecified year and has maintained its status as a manufacturer of pharmaceutical products. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 255 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 9 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 66 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 15.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.34 <BR>Return on Equity: 10.51% <BR>Price to Book: 1.61 <BR><BR>Contact Details: <BR>Address: Mayfair 1-8-303-34, Sardar Patel Road Secunderabad Andhra Pradesh : 500003 <BR>Tel: 91-40-27849700/27844557 <BR>Email: info@godavaridrugs.com <BR>Website: http://www.godavaridrugs.com

Is Godavari Drugs overvalued or undervalued?

As of September 18, 2025, Godavari Drugs is considered very attractive and undervalued, with a PE ratio of 16.95, an EV to EBITDA of 10.77, and a ROCE of 11.66%, significantly lower than peers like Sun Pharma and Divi's Lab, while also showing strong long-term growth potential despite recent underperformance against the Sensex.

As of 18 September 2025, the valuation grade for Godavari Drugs has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued. Key ratios include a PE ratio of 16.95, an EV to EBITDA of 10.77, and a ROCE of 11.66%. <BR><BR>In comparison to its peers, Godavari Drugs stands out with a much lower PE ratio than Sun Pharma (34.46) and Divi's Lab (70.44), both of which are classified as expensive. Additionally, Godavari's PEG ratio is notably at 0.00, suggesting strong growth potential relative to its price. While the stock has underperformed the Sensex over the past year, its recent 5-year return of 136.84% compared to the Sensex's 113.70% highlights its long-term value proposition.

How has been the historical performance of Godavari Drugs?

Godavari Drugs has shown a declining trend in net sales and profits over the past two years, with net sales dropping from 159.62 Cr in Mar'23 to 113.35 Cr in Mar'25, while total assets and liabilities have increased, indicating rising debt levels. Operating profit margins improved slightly, but overall financial performance reflects challenges in the market.

Answer:<BR>The historical performance of Godavari Drugs shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Godavari Drugs reported net sales of 113.35 Cr in Mar'25, a decline from 156.71 Cr in Mar'24 and 159.62 Cr in Mar'23, indicating a downward trend in revenue. The total operating income followed a similar pattern, decreasing from 156.71 Cr in Mar'24 to 113.35 Cr in Mar'25. Raw material costs also decreased to 85.24 Cr in Mar'25 from 121.95 Cr in Mar'24, while total expenditure fell to 101.52 Cr in Mar'25 from 143.41 Cr in Mar'24. Operating profit, excluding other income, was 11.83 Cr in Mar'25, slightly lower than 13.30 Cr in Mar'24, but the operating profit margin improved to 10.44%. Profit before tax decreased to 5.63 Cr in Mar'25 from 6.92 Cr in Mar'24, and profit after tax also fell to 4.38 Cr from 5.55 Cr. The company's total assets increased to 143.08 Cr in Mar'25 from 134.75 Cr in Mar'24, while total liabilities rose to 143.08 Cr from 134.75 Cr, indicating a growing debt level. Cash flow from operating activities decreased to 11.00 Cr in Mar'25 from 18.00 Cr in Mar'24, while cash flow from investing activities worsened to -19.00 Cr. Overall, Godavari Drugs has experienced a decline in sales and profits, alongside an increase in total assets and liabilities, reflecting a challenging financial environment.

Should I buy, sell or hold Godavari Drugs?

Why is Godavari Drugs Ltd falling/rising?

As of 10-Feb, Godavari Drugs Ltd's stock price is at Rs 89.37, down 1.69%, with a 4.07% decline over the last two days and underperformance compared to its sector. The stock shows short-term weakness, reflected by lower moving averages and a 30.59% drop in delivery volume, indicating reduced investor participation.

As of 10-Feb, Godavari Drugs Ltd's stock price is falling, currently at Rs 89.37, reflecting a decrease of Rs 1.54 or 1.69%. The stock has been underperforming, having lost 4.07% over the last two days and showing a performance today that underperformed its sector by 1.65%. <BR><BR>In the past week, the stock has declined by 3.40%, while the benchmark Sensex has gained 0.64%. Although there was a slight increase to an intraday high of Rs 92.82 earlier in the day, the overall trend indicates a lack of momentum. The stock's moving averages indicate that it is currently lower than the 5-day and 20-day moving averages, suggesting short-term weakness despite being higher than the 50-day, 100-day, and 200-day moving averages.<BR><BR>Additionally, there has been a notable drop in investor participation, with delivery volume decreasing by 30.59% compared to the 5-day average. This decline in trading activity may contribute to the downward pressure on the stock price. Overall, these factors collectively explain the current fall in Godavari Drugs Ltd's stock price.

Which are the latest news on Godavari Drugs?

Are Godavari Drugs Ltd latest results good or bad?

Godavari Drugs Ltd's latest results show mixed performance, with a net profit decline and significant drop in operating margins, raising concerns about profitability and financial stability despite a slight increase in net sales. Overall, the outlook appears cautious due to elevated debt levels and a significant stock decline over the past year.

The latest results for Godavari Drugs Ltd indicate a mixed performance, but overall, the outlook appears concerning. In Q2 FY26, the company reported a net profit of ₹1.00 crore, which reflects a decline of 3.85% quarter-on-quarter and 8.26% year-on-year. This suggests that profitability is under pressure.<BR><BR>On the positive side, net sales increased by 11.93% from the previous quarter to ₹26.65 crore, and there was a slight year-on-year growth of 2.15%. However, this revenue growth is overshadowed by a significant drop in operating margins, which fell to 7.47%, the lowest in seven quarters, down from 12.14% in the previous quarter. This margin compression is indicative of severe cost pressures and challenges in the market.<BR><BR>The company's financial health is further complicated by elevated debt levels, with a debt-to-equity ratio of 1.37, which constrains its financial flexibility. Additionally, the stock has underperformed significantly, declining 29.45% over the past year, reflecting a loss of investor confidence.<BR><BR>In summary, while there are some positive signs in terms of revenue growth, the overall results highlight serious concerns regarding profitability, margins, and financial stability, leading to a cautious outlook for the company.